サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1507126

転移性トリプルネガティブ乳癌 (mTNBC)：洞察・疫学・市場予測 (～2034年)

Metastatic triple-negative breast cancer (mTNBC) - Market Insight, Epidemiology, and Market Forecast - 2034

出版日
発行
DelveInsight
ページ情報
英文 200 Pages
納期
2～10営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
転移性トリプルネガティブ乳癌 (mTNBC)：洞察・疫学・市場予測 (～2034年)
出版日: 2024年06月01日
発行: DelveInsight
ページ情報: 英文 200 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、世界の主要7カ国における転移性トリプルネガティブ乳癌 (mTNBC) の市場を調査し、疾患の背景・概要、疫学、治療と管理の概要、市場促進要因と障壁、アンメットニーズ、上市薬およびパイプライン薬のプロファイル、主要国の市場規模の推移・予測、競合情勢などをまとめ、最良の機会を発掘し、市場の潜在力を評価します。

対象地域

  • 米国
  • 欧州5カ国（ドイツ・フランス・イタリア・スペイン・英国）
  • 日本

調査期間：2020年～2034年

レポートハイライト

  • 転移性トリプルネガティブ乳癌 (mTNBC) の市場は、疾患に対する認識の高まりと、医療支出の世界的増加により、今後数年間で変化を示すと考えられています。
  • 企業や研究機関は、転移性トリプルネガティブ乳癌 (mTNBC) の研究開発に影響を与える可能性のある課題を分析し、その機会を探るべく取り組んでいます。開発中の治療薬は、病態を治療/改善するための新規アプローチに焦点を当てています。
  • 大手企業は転移性トリプルネガティブ乳癌 (mTNBC) の治療薬の開発に取り組んでいます。新たな治療薬の上市は市場に大きな影響を与える見通しです。
  • 転移性トリプルネガティブ乳癌 (mTNBC) の新規治療薬の開発には、疾患病態のより深い理解が必要です。
  • 当社の開発段階ごと（第III相および第II相）のパイプラインアセットに関する詳細な分析、さまざまな新興動向、詳細な臨床プロファイル、主なクロスコンペティション、発売日、製品開発活動を含むパイプライン薬の比較分析は、研究開発活動の全体的なシナリオを特定することで、治療ポートフォリオに関する意思決定プロセスにおいてクライアントを支援します。

目次

第1章 重要な洞察

第2章 転移性トリプルネガティブ乳癌 (mTNBC)：エグゼクティブサマリー

第3章 転移性トリプルネガティブ乳癌 (mTNBC)：競合分析

第4章 転移性トリプルネガティブ乳癌 (mTNBC)：市場概要

  • 総市場のシェア (％) の分布：2020年
  • 総市場のシェア (％) の分布：2034年

第5章 転移性トリプルネガティブ乳癌 (mTNBC)：疾患の背景・概要

  • 兆候と症状
  • 病態生理
  • リスク因子
  • 診断

第6章 ペイシェントジャーニー

第7章 転移性トリプルネガティブ乳癌 (mTNBC)：疫学・患者人口

  • 疫学：主要調査結果
  • 前提・根拠：主要7カ国
  • 疫学シナリオ：主要7カ国
    • 主要7カ国における転移性トリプルネガティブ乳癌 (mTNBC) の疫学シナリオ：2020-2034年
  • 疫学：米国
  • 疫学：欧州5カ国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • 英国
  • 疫学：日本

第8章 治療アルゴリズム・現在の治療薬・医療行為

  • 転移性トリプルネガティブ乳癌 (mTNBC) の治療と管理
  • 転移性トリプルネガティブ乳癌 (mTNBC) の治療アルゴリズム

第9章 アンメットニーズ

第10章 転移性トリプルネガティブ乳癌 (mTNBC) 治療の主なエンドポイント

第11章 上市製品

  • 主要7カ国の上市製品リスト
  • 医薬品名・企業名
    • 製品説明
    • 規制のマイルストーン
    • その他の開発活動
    • 重要臨床試験
    • 主要臨床試験の概要

第12章 新興治療薬

  • 主なクロスコンペティション
  • 医薬品名・企業名
    • 製品説明
    • その他の開発活動
    • 臨床開発
    • 安全性と有効性
    • 製品プロファイル

第13章 転移性トリプルネガティブ乳癌 (mTNBC)：主要7カ国市場の分析

  • 主要調査結果
  • 主要7カ国の市場規模
  • 主要7カ国の市場規模：治療薬別

第14章 属性分析

第15章 主要7カ国：市場の展望

  • 米国：市場規模
  • 欧州5カ国：市場規模・展望
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • 英国
  • 日本市場の展望

第16章 転移性トリプルネガティブ乳癌 (mTNBC)：アクセスと償還の概要

第17章 KOLの見解

第18章 市場促進要因

第19章 市場の障壁

第20章 付録

第21章 DelveInsightの能力

第22章 免責事項

第23章 DelveInsightについて

図表

List of Tables

  • Table 1: 7MM Metastatic triple-negative breast cancer (mTNBC) Epidemiology (2020-2034)
  • Table 2: 7MM Metastatic triple-negative breast cancer (mTNBC) Diagnosed and Treatable Cases (2020-2034)
  • Table 3: Metastatic triple-negative breast cancer (mTNBC) Epidemiology in the United States (2020-2034)
  • Table 4: Metastatic triple-negative breast cancer (mTNBC) Diagnosed and Treatable Cases in the United States (2020-2034)
  • Table 5: Metastatic triple-negative breast cancer (mTNBC) Epidemiology in Germany (2020-2034)
  • Table 6: Metastatic triple-negative breast cancer (mTNBC) Diagnosed and Treatable Cases in Germany (2020-2034)
  • Table 7: Metastatic triple-negative breast cancer (mTNBC) Epidemiology in France (2020-2034)
  • Table 8: Metastatic triple-negative breast cancer (mTNBC) Diagnosed and Treatable Cases in France (2020-2034)
  • Table 9: Metastatic triple-negative breast cancer (mTNBC) Epidemiology in Italy (2020-2034)
  • Table 10: Metastatic triple-negative breast cancer (mTNBC) Diagnosed and Treatable Cases in Italy (2020-2034)
  • Table 11: Metastatic triple-negative breast cancer (mTNBC) Epidemiology in Spain (2020-2034)
  • Table 12: Metastatic triple-negative breast cancer (mTNBC) Diagnosed and Treatable Cases in Spain (2020-2034)
  • Table 13: Metastatic triple-negative breast cancer (mTNBC) Epidemiology in the UK (2020-2034)
  • Table 14: Metastatic triple-negative breast cancer (mTNBC) Diagnosed and Treatable Cases in the UK (2020-2034)
  • Table 15: Metastatic triple-negative breast cancer (mTNBC) Epidemiology in Japan (2020-2034)
  • Table 16: Metastatic triple-negative breast cancer (mTNBC) Diagnosed and Treatable Cases in Japan (2020-2034)
  • Table 17: Drug Name, Clinical Trials by Recruitment status
  • Table 18: Drug Name, Clinical Trials by Zone
  • Table 19: Total Seven Major Market Size in USD, Million (2020-2034)
  • Table 20: Region-wise Market Size in USD, Million (2020-2034)
  • Table 21: 7MM-Market Size by Therapy in USD, Million (2020-2034)
  • Table 22: United States Market Size in USD, Million (2020-2034)
  • Table 23: United States Market Size by Therapy in USD, Million (2020-2034)
  • Table 24: Germany Market Size in USD, Million (2020-2034)
  • Table 25: Germany Market Size by Therapy in USD, Million (2020-2034)
  • Table 26: France Market Size in USD, Million (2020-2034)
  • Table 27: France Market Size by Therapy in USD, Million (2020-2034)
  • Table 28: Italy Market Size in USD, Million (2020-2034)
  • Table 29: Italy Market Size by Therapy in USD, Million (2020-2034)
  • Table 30: Spain Market Size in USD, Million (2020-2034)
  • Table 31: Spain Market Size by Therapy in USD, Million (2020-2034)
  • Table 32: United Kingdom Market Size in USD, Million (2020-2034)
  • Table 33: United Kingdom Market Size by Therapy in USD, Million (2020-2034)
  • Table 34: Japan Market Size in USD, Million (2020-2034)
  • Table 35: Japan Market Size by Therapy in USD, Million (2020-2034)

The list of tables is not exhaustive; the final content may vary

List of Figures

  • Figure 1: 7MM Metastatic triple-negative breast cancer (mTNBC) Epidemiology (2020-2034)
  • Figure 2: 7MM Metastatic triple-negative breast cancer (mTNBC) Diagnosed and Treatable Cases (2020-2034)
  • Figure 3: Metastatic triple-negative breast cancer (mTNBC) Epidemiology in the United States (2020-2034)
  • Figure 4: Metastatic triple-negative breast cancer (mTNBC) Diagnosed and Treatable Cases in the United States (2020-2034)
  • Figure 5: Metastatic triple-negative breast cancer (mTNBC) Epidemiology in Germany (2020-2034)
  • Figure 6: Metastatic triple-negative breast cancer (mTNBC) Diagnosed and Treatable Cases in Germany (2020-2034)
  • Figure 7: Metastatic triple-negative breast cancer (mTNBC) Epidemiology in France (2020-2034)
  • Figure 8: Metastatic triple-negative breast cancer (mTNBC) Diagnosed and Treatable Cases in France (2020-2034)
  • Figure 9: Metastatic triple-negative breast cancer (mTNBC) Epidemiology in Italy (2020-2034)
  • Figure 10: Metastatic triple-negative breast cancer (mTNBC) Diagnosed and Treatable Cases in Italy (2020-2034)
  • Figure 11: Metastatic triple-negative breast cancer (mTNBC) Epidemiology in Spain (2020-2034)
  • Figure 12: Metastatic triple-negative breast cancer (mTNBC) Diagnosed and Treatable Cases in Spain (2020-2034)
  • Figure 13: Metastatic triple-negative breast cancer (mTNBC) Epidemiology in the UK (2020-2034)
  • Figure 14: Metastatic triple-negative breast cancer (mTNBC) Diagnosed and Treatable Cases in the UK (2020-2034)
  • Figure 15: Metastatic triple-negative breast cancer (mTNBC) Epidemiology in Japan (2020-2034)
  • Figure 16: Metastatic triple-negative breast cancer (mTNBC) Diagnosed and Treatable Cases in Japan (2020-2034)
  • Figure 17: Drug Name, Clinical Trials by Recruitment status
  • Figure 18: Drug Name, Clinical Trials by Zone
  • Figure 19: Total Seven Major Market Size in USD, Million (2020-2034)
  • Figure 20: Region-wise Market Size in USD, Million (2020-2034)
  • Figure 21: 7MM-Market Size by Therapy in USD, Million (2020-2034)
  • Figure 22: United States Market Size in USD, Million (2020-2034)
  • Figure 23: United States Market Size by Therapy in USD, Million (2020-2034)
  • Figure 24: Germany Market Size in USD, Million (2020-2034)
  • Figure 25: Germany Market Size by Therapy in USD, Million (2020-2034)
  • Figure 26: France Market Size in USD, Million (2020-2034)
  • Figure 27: France Market Size by Therapy in USD, Million (2020-2034)
  • Figure 28: Italy Market Size in USD, Million (2020-2034)
  • Figure 29: Italy Market Size by Therapy in USD, Million (2020-2034)
  • Figure 30: Spain Market Size in USD, Million (2020-2034)
  • Figure 31: Spain Market Size by Therapy in USD, Million (2020-2034)
  • Figure 32: United Kingdom Market Size in USD, Million (2020-2034)
  • Figure 33: United Kingdom Market Size by Therapy in USD, Million (2020-2034)
  • Figure 34: Japan Market Size in USD, Million (2020-2034)
  • Figure 35: Japan Market Size by Therapy in USD, Million (2020-2034)

The list of figures is not exhaustive; the final content may vary

目次
Product Code: DIMI0909

DelveInsight's "Metastatic triple-negative breast cancer (mTNBC) - Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Metastatic triple-negative breast cancer (mTNBC), historical and forecasted epidemiology as well as the Metastatic triple-negative breast cancer (mTNBC) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Metastatic triple-negative breast cancer (mTNBC) market report provides current treatment practices, emerging drugs, Metastatic triple-negative breast cancer (mTNBC) market share of the individual therapies, current and forecasted Metastatic triple-negative breast cancer (mTNBC) market size from 2020 to 2034 segmented by seven major markets. The Report also covers current Metastatic triple-negative breast cancer (mTNBC) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2020-2034

Metastatic triple-negative breast cancer (mTNBC) Disease Understanding and Treatment Algorithm

The DelveInsight Metastatic triple-negative breast cancer (mTNBC) market report gives a thorough understanding of the Metastatic triple-negative breast cancer (mTNBC) by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Metastatic triple-negative breast cancer (mTNBC).

Treatment

It covers the details of conventional and current medical therapies available in the Metastatic triple-negative breast cancer (mTNBC) market for the treatment of the condition. It also provides Metastatic triple-negative breast cancer (mTNBC) treatment algorithms and guidelines in the United States, Europe, and Japan.

Metastatic triple-negative breast cancer (mTNBC) Epidemiology

The Metastatic triple-negative breast cancer (mTNBC) epidemiology division provide insights about historical and current Metastatic triple-negative breast cancer (mTNBC) patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Metastatic triple-negative breast cancer (mTNBC) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2020 to 2034.

Country Wise-Metastatic triple-negative breast cancer (mTNBC) Epidemiology

The epidemiology segment also provides the Metastatic triple-negative breast cancer (mTNBC) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Metastatic triple-negative breast cancer (mTNBC) Drug Chapters

Drug chapter segment of the Metastatic triple-negative breast cancer (mTNBC) report encloses the detailed analysis of Metastatic triple-negative breast cancer (mTNBC) marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Metastatic triple-negative breast cancer (mTNBC) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Metastatic triple-negative breast cancer (mTNBC) treatment.

Metastatic triple-negative breast cancer (mTNBC) Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Metastatic triple-negative breast cancer (mTNBC) treatment.

Metastatic triple-negative breast cancer (mTNBC) Market Outlook

The Metastatic triple-negative breast cancer (mTNBC) market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Metastatic triple-negative breast cancer (mTNBC) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Metastatic triple-negative breast cancer (mTNBC) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Metastatic triple-negative breast cancer (mTNBC) market in 7MM is expected to change in the study period 2020-2034.

Key Findings

This section includes a glimpse of the Metastatic triple-negative breast cancer (mTNBC) market in 7MM.

The United States Market Outlook

This section provides the total Metastatic triple-negative breast cancer (mTNBC) market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Metastatic triple-negative breast cancer (mTNBC) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Metastatic triple-negative breast cancer (mTNBC) market size and market size by therapies in Japan is also mentioned.

Metastatic triple-negative breast cancer (mTNBC) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Metastatic triple-negative breast cancer (mTNBC) market or expected to get launched in the market during the study period 2020-2034. The analysis covers Metastatic triple-negative breast cancer (mTNBC) market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Metastatic triple-negative breast cancer (mTNBC) Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Metastatic triple-negative breast cancer (mTNBC) key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Metastatic triple-negative breast cancer (mTNBC) emerging therapies.

Reimbursement Scenario in Metastatic triple-negative breast cancer (mTNBC)

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Metastatic triple-negative breast cancer (mTNBC) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Metastatic triple-negative breast cancer (mTNBC) market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Metastatic triple-negative breast cancer (mTNBC) Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

  • The report covers the descriptive overview of Metastatic triple-negative breast cancer (mTNBC), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Metastatic triple-negative breast cancer (mTNBC) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Metastatic triple-negative breast cancer (mTNBC) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Metastatic triple-negative breast cancer (mTNBC) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Metastatic triple-negative breast cancer (mTNBC) market

Report Highlights:

  • In the coming years, Metastatic triple-negative breast cancer (mTNBC) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Metastatic triple-negative breast cancer (mTNBC) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Metastatic triple-negative breast cancer (mTNBC). Launch of emerging therapies will significantly impact the Metastatic triple-negative breast cancer (mTNBC) market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Metastatic triple-negative breast cancer (mTNBC)
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Metastatic triple-negative breast cancer (mTNBC) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Metastatic triple-negative breast cancer (mTNBC) Pipeline Analysis
  • Metastatic triple-negative breast cancer (mTNBC) Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Metastatic triple-negative breast cancer (mTNBC) Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage
  • Metastatic triple-negative breast cancer (mTNBC) Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Metastatic triple-negative breast cancer (mTNBC) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions:

Market Insights:

  • What was the Metastatic triple-negative breast cancer (mTNBC) market share (%) distribution in 2020 and how it would look like in 2034?
  • What would be the Metastatic triple-negative breast cancer (mTNBC) total market size as well as market size by therapies across the 7MM during the forecast period (2024-2034)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Metastatic triple-negative breast cancer (mTNBC) market size during the forecast period (2024-2034)?
  • At what CAGR, the Metastatic triple-negative breast cancer (mTNBC) market is expected to grow in 7MM during the forecast period (2020-2034)?
  • What would be the Metastatic triple-negative breast cancer (mTNBC) market outlook across the 7MM during the forecast period (2020-2034)?
  • What would be the Metastatic triple-negative breast cancer (mTNBC) market growth till 2032, and what will be the resultant market Size in the year 2034?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the Metastatic triple-negative breast cancer (mTNBC)?
  • What is the historical Metastatic triple-negative breast cancer (mTNBC) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Metastatic triple-negative breast cancer (mTNBC) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Metastatic triple-negative breast cancer (mTNBC)?
  • Out of all 7MM countries, which country would have the highest prevalent population of Metastatic triple-negative breast cancer (mTNBC) during the forecast period (2020-2034)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2020-2034)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

  • What are the current options for the Metastatic triple-negative breast cancer (mTNBC) treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Metastatic triple-negative breast cancer (mTNBC) in the USA, Europe, and Japan?
  • What are the Metastatic triple-negative breast cancer (mTNBC) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Metastatic triple-negative breast cancer (mTNBC)?
  • How many therapies are developed by each company for Metastatic triple-negative breast cancer (mTNBC) treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Metastatic triple-negative breast cancer (mTNBC) treatment?
  • What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Metastatic triple-negative breast cancer (mTNBC) therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Metastatic triple-negative breast cancer (mTNBC) and their status?
  • What are the key designations that have been granted for the emerging therapies for Metastatic triple-negative breast cancer (mTNBC)?
  • What are the global historical and forecasted market of Metastatic triple-negative breast cancer (mTNBC)?

Reasons to buy:

  • The report will help in developing business strategies by understanding trends shaping and driving the Metastatic triple-negative breast cancer (mTNBC) market
  • To understand the future market competition in the Metastatic triple-negative breast cancer (mTNBC) market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Metastatic triple-negative breast cancer (mTNBC) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Metastatic triple-negative breast cancer (mTNBC) market
  • To understand the future market competition in the Metastatic triple-negative breast cancer (mTNBC) market

Table of Contents

1. Key Insights

2. Executive Summary of Metastatic triple-negative breast cancer (mTNBC)

3. Competitive Intelligence Analysis for Metastatic triple-negative breast cancer (mTNBC)

4. Metastatic triple-negative breast cancer (mTNBC): Market Overview at a Glance

  • 4.1. Metastatic triple-negative breast cancer (mTNBC) Total Market Share (%) Distribution in 2020
  • 4.2. Metastatic triple-negative breast cancer (mTNBC) Total Market Share (%) Distribution in 2034

5. Metastatic triple-negative breast cancer (mTNBC): Disease Background and Overview

  • 5.1. Introduction
  • 5.2. Sign and Symptoms
  • 5.3. Pathophysiology
  • 5.4. Risk Factors
  • 5.5. Diagnosis

6. Patient Journey

7. Metastatic triple-negative breast cancer (mTNBC) Epidemiology and Patient Population

  • 7.1. Epidemiology Key Findings
  • 7.2. Assumptions and Rationale: 7MM
  • 7.3. Epidemiology Scenario: 7MM
    • 7.3.1. Metastatic triple-negative breast cancer (mTNBC) Epidemiology Scenario in the 7MM (2020-2034)
  • 7.4. United States Epidemiology
    • 7.4.1. Metastatic triple-negative breast cancer (mTNBC) Epidemiology Scenario in the United States (2020-2034)
  • 7.5. EU-5 Country-wise Epidemiology
    • 7.5.1. Germany Epidemiology
      • 7.5.1.1. Metastatic triple-negative breast cancer (mTNBC) Epidemiology Scenario in Germany (2020-2034)
    • 7.5.2. France Epidemiology
      • 7.5.2.1. Metastatic triple-negative breast cancer (mTNBC) Epidemiology Scenario in France (2020-2034)
    • 7.5.3. Italy Epidemiology
      • 7.5.3.1. Metastatic triple-negative breast cancer (mTNBC) Epidemiology Scenario in Italy (2020-2034)
    • 7.5.4. Spain Epidemiology
      • 7.5.4.1. Metastatic triple-negative breast cancer (mTNBC) Epidemiology Scenario in Spain (2020-2034)
    • 7.5.5. United Kingdom Epidemiology
      • 7.5.5.1. Metastatic triple-negative breast cancer (mTNBC) Epidemiology Scenario in the United Kingdom (2020-2034)
    • 7.5.6. Japan Epidemiology
      • 7.5.6.1. Metastatic triple-negative breast cancer (mTNBC) Epidemiology Scenario in Japan (2020-2034)

8. Treatment Algorithm, Current Treatment, and Medical Practices

  • 8.1. Metastatic triple-negative breast cancer (mTNBC) Treatment and Management
  • 8.2. Metastatic triple-negative breast cancer (mTNBC) Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Metastatic triple-negative breast cancer (mTNBC) Treatment

11. Marketed Products

  • 11.1. List of Marketed Products in the 7MM
  • 11.2. Drug Name: Company Name
    • 11.2.1. Product Description
    • 11.2.2. Regulatory Milestones
    • 11.2.3. Other Developmental Activities
    • 11.2.4. Pivotal Clinical Trials
    • 11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

  • 12.1. Key Cross
  • 12.2. Drug Name: Company Name
    • 12.2.1. Product Description
    • 12.2.2. Other Developmental Activities
    • 12.2.3. Clinical Development
    • 12.2.4. Safety and Efficacy
    • 12.2.5. Product Profile

List to be continued in report

13. Metastatic triple-negative breast cancer (mTNBC): Seven Major Market Analysis

  • 13.1. Key Findings
  • 13.2. Metastatic triple-negative breast cancer (mTNBC) Market Size in 7MM
  • 13.3. Metastatic triple-negative breast cancer (mTNBC) Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

  • 15.1. United States: Market Size
    • 15.1.1. Metastatic triple-negative breast cancer (mTNBC) Total Market Size in the United States
    • 15.1.2. Metastatic triple-negative breast cancer (mTNBC) Market Size by Therapies in the United States
  • 15.2. EU-5 countries: Market Size and Outlook
  • 15.3. Germany Market Size
    • 15.3.1. Metastatic triple-negative breast cancer (mTNBC) Total Market Size in Germany
    • 15.3.2. Metastatic triple-negative breast cancer (mTNBC) Market Size by Therapies in Germany
  • 15.4. France Market Size
    • 15.4.1. Metastatic triple-negative breast cancer (mTNBC) Total Market Size in France
    • 15.4.2. Metastatic triple-negative breast cancer (mTNBC) Market Size by Therapies in France
  • 15.5. Italy Market Size
    • 15.5.1. Metastatic triple-negative breast cancer (mTNBC) Total Market Size in Italy
    • 15.5.2. Metastatic triple-negative breast cancer (mTNBC) Market Size by Therapies in Italy
  • 15.6. Spain Market Size
    • 15.6.1. Metastatic triple-negative breast cancer (mTNBC) Total Market Size in Spain
    • 15.6.2. Metastatic triple-negative breast cancer (mTNBC) Market Size by Therapies in Spain
  • 15.7. United Kingdom Market Size
    • 15.7.1. Metastatic triple-negative breast cancer (mTNBC) Total Market Size in the United Kingdom
    • 15.7.2. Metastatic triple-negative breast cancer (mTNBC) Market Size by Therapies in the United Kingdom
  • 15.8. Japan Market Outlook
    • 15.8.1. Japan Market Size
    • 15.8.2. Metastatic triple-negative breast cancer (mTNBC) Total Market Size in Japan
    • 15.8.3. Metastatic triple-negative breast cancer (mTNBC) Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Metastatic triple-negative breast cancer (mTNBC)

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

  • 20.1. Bibliography
  • 20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

The table of contents is not exhaustive; the final content may vary.